Phase III, randomised, double-blind, placebo-controlled, multicentre trial to evaluate the efficacy and safety of rhGAD65 to preserve endogenous beta cell function in adolescents and adults with recently diagnosed type 1 diabetes, carrying the genetic HLA DR3-DQ2 haplotype: the DIAGNODE-3 study protocol

Introduction Type 1 diabetes (T1D) is an autoimmune disease leading to the destruction of the insulin-producing beta cells resulting in insulin deficiency and hyperglycaemic. Today, no approved therapy exists to halt this detrimental immunologic process. In a recent phase 2b study, intralymphatic ad...

Full description

Bibliographic Details

Published in:	BMJ Open
Main Authors:	Marcus Lind, Johnny Ludvigsson, Christoph Nowak, Linnea Eriksson, Pedro F Teixeira, Martina Widman, Anton Lindqvist, Rosaura Casas, Ulf Hannelius
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2022-10-01
Online Access:	https://bmjopen.bmj.com/content/12/10/e061776.full